Amgen and its partner Allergan announced Friday that their ABP 980, a trastuzumab biosimilar referencing Herceptin, has gained a positive opinion for marketing from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Amgen and its partner Allergan announced Friday that their ABP 980, a trastuzumab biosimilar referencing Herceptin, has gained a positive opinion for marketing (for all indications of the reference Herceptin) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Amgen—Allergan’s marketing application for ABP 980 was supported by analytical, pharmacokinetic, and clinical data, as well as pharmacology and toxicology data. The phase 3 comparative efficacy, safety, and immunogenicity study was conducted in adult patients with HER2-positive early breast cancer.
Before the companies are granted a final clearance to market the drug in the European Union, the European Commission (EC) will review the CHMP opinion. If the EC grants a centralized marketing authorization, the biosimilar may be sold in the 28 member states of the European Union. Members of the European Economic Area will make corresponding decisions on the basis of the EC’s verdict.
If approved, the biosimilar will compete with Celltrion’s Herzuma, a trastuzumab biosimilar that will be distributed by Mundipharma in 7 EU nations, and Samsung Bioepis’ Ontruzant, another biosimilar of the reference Herceptin, that has recently launched by Merck—operating under the trade name MSD—in the United Kingdom.
Meanwhile, in the United States, patients await the arrival of a biosimilar trastuzumab. Biocon, sponsor of Ogivri, the only FDA-approved trastuzumab biosimilar to date, has not yet announced a launch date for its product, and Celltrion and Teva’s CT-P6 and Pfizer’s PF-05280014 are both awaiting regulatory decisions by the FDA.
Amgen and Allergan have also developed the FDA- and EMA-approved adalimumab (Humira) biosimilar that will eventually be marketed as Amjevita and Amgevita, as well as a bevacizumab (Avastin) biosimilar that will eventually enter the market as Mvasi. The partnership is also developing ABP 798, a biosimilar rituximab; ABP 710, a biosimilar infliximab; and ABP 494, a biosimilar cetuximab. Amgen reports that it has another 3 undisclosed biosimilar products under development.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.